Systemic sclerosis (scleroderma) trials in Brazil

In Brazil 6 Also abroad 213

6 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
Where
Belo Horizonte, Porto Alegre, Rio de Janeiro, Salvador, São Paulo
Age
5 years to 80 years
People
1,072 worldwide
Run by
AstraZeneca
See details and how to joinNCT07691970
Phase 3Taking people
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
Where
Curitiba, Porto Alegre, Recife, Salvador, São Paulo, Valinhos
Age
18 years and over
People
448 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07497087 · EU 2025-523884-39-00
Phase 2/3Taking people
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
Where
Belo Horizonte, Curitiba, Juiz de Fora, Porto Alegre, Salvador, São Paulo
Age
18 years and over
People
300 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT05878717 · EU 2023-503219-14-01
Phase 2Taking people
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Where
Brasília, Cuiabá, Porto Alegre, Rio Grande, São Paulo
Age
18 years and over
People
90 worldwide
Run by
Artiva Biotherapeutics, Inc.
See details and how to joinNCT06991114 · EU 2025-520461-41-00
Phase 4Taking people
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
Where
São Paulo
Age
12 years to 59 years
People
477
Run by
University of Sao Paulo General Hospital
See details and how to joinNCT07087912
Phase 1Taking people
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Where
Porto Alegre, Salvador, São Paulo
Age
18 years and over
People
125 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07115745 · EU 2024-517681-41-00